ARRIS to Showcase Optical Transport Solutions at KCTA Show in Seoul

ARRIS (Nasdaq: ARRS) will demonstrate its broadband access, advanced video and transport solutions to Korean service providers at the KCTA Show in Seoul, Korea, March 3-6, 2010.  Korean cable operators and ISPs face stiff competition from national telecoms providers in delivering ultra high speed data service and video, and are looking for the most cost-efficient and optimized infrastructure solutions to meet their growing customer demands.

The ARRIS booth will highlight:

  • The C4® CMTS' DOCSIS® 3.0 Upstream and Downstream Channel Bonding capabilities that deliver data speeds in excess of 100 Mbp/s Upstream and 320 Mbp/s Downstream.
  • ARRIS optical access and transport solutions, the CHP (Converged Head End Platform) with CORWave™ multi wavelength transmitters, CORView™ Element Management Systems, Opti Max 3100 and 4100 1 GHz segmentable nodes.
  • New optical products designed for hybrid and fiber-deep architectures, including CORWave II multi wavelength transmitters supporting up to 16 independent 1 GHz transport streams and reaches of up to 65 km; as well as the FTTMax RFoG Optical Network Units and FTTMax™ E-PON Optical Line Terminals and Optical Network Units.
  • Advanced transcoding and video compression capabilities utilizing the ARRIS EGT VIPr™ and Encore dual-pass video encoder.
  • ARRIS Managed Content Distribution architectures through the ARRIS ConvergeMedia™ management platform.
  • The ARRIS Fixed Mobile Convergence platform for seamless mobile to fixed-line voice transfer.

Additionally, Todd Kessler, ARRIS VP of Product Management, will speak in the afternoon session on March 4th, giving a talk on:  'New Technologies for Enhancing Digital Cable TV's Market Competitiveness'.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.